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Could N-terminal pro-BNP peptide
be a useful marker for prediction
of cardiac arrests in hemodialysis
patients?
Kidney International (2009) 75, 440; doi:10.1038/ki.2008.582
To the Editor: We read with interest the article by
Ostermann.1 They reported cardiac arrests in the dialysis
unit are relatively rare events but carry a poor prognosis.
The incidence of cardiac disease in dialysis patients was
reported as very high, but there has been few markers to
predict the cardiovascular mortality or arrhythmic events.
Recently, N-terminal pro-brain natriuretic peptide (NT-pro-
BNP) has become important diagnostic tools for assessing
cardiac dysfunctions. Although not extensively studied in
dialysis patients, some authors studied the relationship
between cardiovascular mortality and NT-pro-BNP levels.2,3
Wang et al.2 reported that NT-pro-BNP was an important
risk predictor of cardiovascular congestion, mortality, and
adverse cardiovascular outcomes in chronic peritoneal
dialysis patients, and Satyan et al.3 demonstrated that
NT-pro-BNP level strongly correlated with left ventricular
systolic dysfunction and was associated more strongly with
mortality than cardiac troponin T level in asymptomatic
hemodialysis patients. Furthermore, some authors showed
that raised NT-pro-BNP levels predicted occurrence of
symptomatic ventricular arrhythmias.4
Because cardiovascular disease is the main cause of
morbidity and mortality in patients undergoing hemodia-
lysis, NT-pro-BNP, a biological marker of left ventricular
dysfunction, might enable us to identify high-risk asympto-
matic early hemodialyzed patients, leading to aggressive
evaluation of cardiac dysfunctions and appropriate, targeted
therapeutic intervention.
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I agree with Shin and Lee that there is an association
between elevated or rising N-terminal pro-brain natriure-
tic peptide (NT-pro-BNP) levels and cardiovascular mor-
bidity in patients with chronic kidney disease. However, in
dialysis patients, the exact role and interpretation of this
substance remains unclear. Firstly, NT-pro-BNP is pre-
dominantly cleared by glomerular filtration which means
that the serum level not only depends on cardiac and
volume status but also on degree of residual renal
function.1,2 Oligoanuric hemodialysis patients tend to
have significantly higher NT-pro-BNP levels compared to
hemodialysis patients with residual diuresis.2 In addition,
clearance during hemodialysis can vary depending on the
dialyzer used, which makes the interpretation of serum
levels dependent on the timing in relationship to
hemodialysis. Wahl et al.3 measured NT-pro-BNP levels
pre- and post hemodialysis and found that treatment with
a high-flux membrane caused a decrease in NT-pro-BNP by
18.4%, whereas treatment with a low-flux membrane led to
an increase in NT-pro-BNP by 16.8%, probably mainly as a
result of hemoconcentration. For NT-pro-BNP to become a
useful tool in the clinical management of dialysis patients,
it is essential to reevaluate the exact cut-off values, taking
residual renal function, type of dialysis and dialysis
membrane and underlying comorbid factors into account.
Furthermore, it is still unclear whether NT-pro-BNP levels
merely serve as indicators of an increased risk or can in
fact be used as targets for specific therapies. It is possible
that NT-pro-BNP may be useful in risk stratification when
considering invasive therapeutic interventions like more
frequent dialysis or an implantable cardioverter defibril-
lator. Until we have these answers, NT-pro-BNP only
remains a marker of cardiovascular morbidity in dialysis
patients.
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